14 High Growth Large Cap Stocks to Buy Right Now

9. Natera, Inc. (NASDAQ:NTRA)

M-Cap: $32.2 billion

Number of Hedge Fund Holders: 70

5-year Revenue Growth: ~42.3%

Natera, Inc. (NASDAQ:NTRA) is one of the High Growth Large Cap Stocks to Buy Right Now. On December 18, the company announced publication of the findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. CALGB (Alliance)/SWOG 80702 assessed predictive value of postoperative personalized circulating tumor DNA (ctDNA) in patients having stage III colorectal cancer (CRC).

Furthermore, it was mentioned that, for patients having detectable ctDNA after surgery, the addition of celecoxib to standard chemotherapy improved both DFS and OS. Apart from highlighting Signatera’s predictive abilities in the setting, the publication underscores its value as a prognostic marker for disease recurrence and survival.

In a separate update, on December 17, Jefferies lifted the price objective on the company’s stock to $275.00 from $230.00, while maintaining a “Buy” rating. The firm cited Natera, Inc. (NASDAQ:NTRA)’s consistent pattern of surpassing expectations and raising guidance. Notably, the firm also noted increased average selling price from commercial coverage, new indications, as well as guidelines as the growth factors, with American College of Obstetricians and Gynecologists (ACOG) potentially acting as a catalyst for non-invasive prenatal testing (NIPT).

Elsewhere, Natera, Inc. (NASDAQ:NTRA), along with Quantum Leap Healthcare Collaborative, announced about publication of new findings from the I-SPY 2 trial in Nature Communications. Notably, the study assessed how Signatera can refine risk assessment in patients having early-stage breast cancer whose tumors resist neoadjuvant therapy (NAT).

Natera, Inc. (NASDAQ:NTRA) happens to be a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health.